Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the impact of his clinical trial, CHRONOS-1, on current and future cancer research. He states that the compounds of drugs are affective in any stage of disease and that the data continues to show the important roles of PI3K Inhibitors. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Impact of CHRONOS-1 Data on Current & Future Clinical Research
